Страна: Сингапур
Език: английски
Източник: HSA (Health Sciences Authority)
CALCITRIOL
DKSH SINGAPORE PTE. LTD.
A11CC04
0.25 mcg
CAPSULE, LIQUID FILLED
CALCITRIOL 0.25 mcg
ORAL
Prescription Only
Catalent Germany Eberbach GmbH
ACTIVE
1990-02-10
Jun 2013 1 ROCALTROL® Calcitriol 1. DESCRIPTION 1.1 THERAPEUTIC / PHARMACOLOGIC CLASS OF DRUG Biologically active form of vitamin D 3. ATC code: A11CC04. 1.2 TYPE OF DOSAGE FORM Capsules containing 0.25 µg and 0.5 µg calcitriol. 1.3 ROUTE OF ADMINISTRATION Orally. 1.4 QUALITATIVE AND QUANTITATIVE COMPOSITION _Active ingredient:_ synthetic calcitriol (biologically active form of vitamin D 3 ). _Chemical names: _1 , 25 - dihydroxycholecalciferol; (5Z-/E)- 9, 10-secocholesta - 5, 7, 10 (19) - triene - 1 , 3 , 25 - triol._ _ Capsules 0.25 µg and 0.5 µg. _Excipients:_ Capsules: Butylhydroxyanisol, butylhydroxytoluene, medium-chain triglycerides, gelatin, glycerol 85%, hydrogenated products of partially hydrolyzed starch, titanium dioxide (E 171), red and yellow iron oxide (E 172). 2. CLINICAL PARTICULARS 2.1 THERAPEUTIC INDICATION(S) Established postmenopausal osteoporosis. Renal osteodystrophy in patients with chronic renal failure, particularly those undergoing hemodialysis. Postsurgical hypoparathyroidism. Idiopathic hypoparathyroidism. Pseudohypoparathyroidism. Vitamin D-dependent rickets. Hypophosphatemic vitamin D-resistant rickets. 2.2 DOSAGE AND ADMINISTRATION The optimal daily dose of Rocaltrol must be carefully determined for each patient on the basis of the serum calcium level. Rocaltrol therapy should always be started at the lowest possible dose and should not be increased without careful monitoring of serum calcium _(see Patient monitoring)._ Jun 2013 2 A prerequisite for optimal efficacy of Rocaltrol is adequate but not excessive calcium intake at the beginning of therapy. C Прочетете целия документ
ROCALTROL ® Calcitriol 1. DESCRIPTION 1.1 THERAPEUTIC / PHARMACOLOGIC CLASS OF DRUG Biologically active form of vitamin D 3. ATC code: A11CC04. 1.2 TYPE OF DOSAGE FORM Capsules containing 0.25 µg and 0.5 µg calcitriol. 1.3 ROUTE OF ADMINISTRATION Orally. 1.4 QUALITATIVE AND QUANTITATIVE COMPOSITION _Active ingredient:_ synthetic calcitriol (biologically active form of vitamin D 3 ). _Chemical names: _ 1 α , 25 - dihydroxycholecalciferol; (5Z-/E)- 9, 10-secocholesta - 5, 7, 10 (19) - triene - 1 α , 3 β , 25 - triol. Capsules 0.25 µg and 0.5 µg. _Excipients:_ Capsules: Butylhydroxyanisol, butylhydroxytoluene, medium-chain triglycerides, gelatin, glycerol 85%, hydrogenated products of partial ly hydrolyzed starch, titanium dioxide (E 171), red and yellow iron oxide (E 172). 2. CLINICAL PARTICULARS 2.1 THERAPEUTIC INDICATION(S) Established postmenopausal osteoporosis. Renal osteodystrophy in patients with chronic renal failure, particularly those undergoing hemodialysis. Postsurgical hypoparathyroidism. Idiopathic hypoparathyroidism. Pseudohypoparathyroidism. Vitamin D-dependent rickets. Hypophosphatemic vitamin D-resistant rickets. 2.2 DOSAGE AND ADMINISTRATION The optimal daily dose of Rocaltrol must be carefully determined for each patient on the basis of the serum calcium level. Rocaltrol therapy should always be started at the lowest possible dose and should not be increased without careful monitoring of serum calcium _(see Patient monitoring)._ A prerequisite for optimal efficacy of Rocaltrol is adequate but not excessive calcium intake at the beginning of therapy. Calcium supplements may be necessary and should be administered according to local guidelines. Because of improved calcium absorption from the gastrointestinal tract, some patients on Rocaltrol may be maintained on a lower calcium intake. Patients who tend to develop hypercalcaemia may require only low doses of calcium or no supplementation at all. _Patient monitoring _ During the stabilization phase of treatment with Rocaltrol, serum calcium Прочетете целия документ